Loading...
Background: Emerging antimicrobial resistance is and will remain one of the most daunting problems in health care. Therefore, great enthusiasm attends the development and introduction of new classes of antimicrobials that are effective against multidrug-resistant organisms. One such class of agents is the streptogramins, and the first of these, quinupristin/dalfopristin (Synercid®, Rhone-Poulenc Rorer) has just been approved by the FDA for use in resistant gram-positive infections.
Streptogramins A (dalfopristin) and B (quinupristin) are macrolide-like agents naturally synthesized by streptomyces organisms. Type A are cyclopeptides and type B are cyclic hexadepsipeptides. They act at the ribosomal level, binding to the 50s subunit to inhibit…